Price T Rowe Associates Inc Kymera Therapeutics, Inc. Transaction History

Price T Rowe Associates Inc

  • $883 Billion
  • Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 6,859,202 shares of KYMR stock, worth $273 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
6,859,202
Previous 6,702,450 2.34%
Holding current value
$273 Million
Previous $183 Million 63.17%
% of portfolio
0.03%
Previous 0.02%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$21.05 - $48.6 $3.3 Million - $7.62 Million
156,752 Added 2.34%
6,859,202 $299 Million
Q1 2025

May 14, 2025
SELL
$27.37 - $44.36 $4.59 Million - $7.45 Million
-167,883 Reduced 2.44%
6,702,450 $183 Million
Q4 2024

Feb 14, 2025
BUY
$39.06 - $51.84 $8.78 Million - $11.7 Million
224,859 Added 3.38%
6,870,333 $276 Million
Q3 2024

Nov 14, 2024
BUY
$30.16 - $52.4 $7.69 Million - $13.4 Million
254,816 Added 3.99%
6,645,474 $315 Million
Q2 2024

Aug 14, 2024
BUY
$29.85 - $39.42 $1.75 Million - $2.31 Million
58,646 Added 0.93%
6,390,658 $191 Million
Q1 2024

May 15, 2024
BUY
$22.9 - $43.57 $22.8 Million - $43.4 Million
996,300 Added 18.67%
6,332,012 $255 Million
Q4 2023

Feb 14, 2024
BUY
$10.97 - $26.84 $3.05 Million - $7.47 Million
278,287 Added 5.5%
5,335,712 $136 Million
Q3 2023

Nov 14, 2023
BUY
$13.9 - $23.88 $698,850 - $1.2 Million
50,277 Added 1.0%
5,057,425 $70.3 Million
Q2 2023

Aug 14, 2023
BUY
$22.4 - $34.92 $7.63 Million - $11.9 Million
340,467 Added 7.3%
5,007,148 $115 Million
Q1 2023

May 15, 2023
BUY
$24.84 - $38.75 $7.14 Million - $11.1 Million
287,522 Added 6.57%
4,666,681 $138 Million
Q4 2022

Feb 14, 2023
BUY
$19.57 - $30.92 $5.51 Million - $8.7 Million
281,447 Added 6.87%
4,379,159 $109 Million
Q3 2022

Nov 14, 2022
SELL
$20.91 - $34.27 $23.6 Million - $38.6 Million
-1,126,974 Reduced 21.57%
4,097,712 $89.2 Million
Q2 2022

Aug 15, 2022
BUY
$14.13 - $42.55 $18.8 Million - $56.6 Million
1,329,481 Added 34.13%
5,224,686 $103 Million
Q1 2022

May 16, 2022
BUY
$35.3 - $64.68 $12.2 Million - $22.3 Million
344,677 Added 9.71%
3,895,205 $165 Million
Q4 2021

Feb 14, 2022
BUY
$49.91 - $65.56 $15.8 Million - $20.8 Million
317,331 Added 9.81%
3,550,528 $225 Million
Q3 2021

Nov 15, 2021
BUY
$47.8 - $66.66 $66.4 Million - $92.5 Million
1,388,271 Added 75.25%
3,233,197 $190 Million
Q2 2021

Aug 16, 2021
BUY
$31.08 - $51.95 $28.3 Million - $47.4 Million
911,948 Added 97.75%
1,844,926 $89.5 Million
Q1 2021

May 17, 2021
BUY
$35.64 - $85.46 $19.3 Million - $46.2 Million
540,902 Added 137.96%
932,978 $36.3 Million
Q4 2020

Feb 16, 2021
BUY
$28.07 - $87.83 $11 Million - $34.4 Million
392,076 New
392,076 $24.3 Million

Others Institutions Holding KYMR

# of Institutions
217
Shares Held
72.2M
Call Options Held
178K
Put Options Held
64.6K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.18B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Price T Rowe Associates Inc Portfolio

Follow Price T Rowe Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email